

CURRICULUM VITAE - FORMATO EUROPEO

INFORMAZIONI PERSONALI

Nome Lucia Del Mastro
Indirizzo Via G. Bettolo, 145/6 - Genova
Telefono 010-5558908
Fax 010-5556383
E-mail lucia.delmastro@hsanmartino.it
Nazionalità Italiana
Data di nascita 11/04/1964
Stato civile: vedova; 2 figli

ESPERIENZA LAVORATIVA

1993-1996: Ricercatore a contratto

Istituto Nazionale per la Ricerca sul Cancro – L.go Rosanna Benzi, 10-16132 Genova

Principali mansioni e responsabilità: Sviluppo di progetti di ricerca sul carcinoma mammario

1997-98: Dirigente Medico

Azienda Ospedaliera Pisana

Principali mansioni e responsabilità: Attività di assistenza e ricerca sul carcinoma mammario

1998-2009: Dirigente Medico

Istituto Nazionale per la Ricerca sul Cancro – L.go Rosanna Benzi, 10-16132 Genova

Principali mansioni e responsabilità: Assistenza. Coordinatore “Disease Management Team” del carcinoma mammario. Coordinamento attività di ricerca nel carcinoma mammario-

2009-ad oggi: Direttore Struttura Semplice Sviluppo Terapie Innovative - Coordinatore del “Disease Management Team” del carcinoma mammario

IRCCS AOU San Martino –IST Istituto Nazionale per la Ricerca sul Cancro – L.go Rosanna Benzi, 10-16132 Genova

Principali mansioni e responsabilità:

1. Coordinamento attività di ricerca nuovi farmaci e nuove tecnologie.
2. Coordinamento attività di ricerca nel carcinoma mammario
3. Coordinamento del Percorso Diagnostico Terapeutico delle pazienti con carcinoma mammario, in qualità di Coordinatore del “Disease Management Team”

ISTRUZIONE E FORMAZIONE

1989: laurea in Medicina e Chirurgia (110 e lode/110). Università degli studi di Napoli, Federico II

1993: Specializzazione in Oncologia Medica (70 e lode/70), Università degli studi di Napoli, Federico II

CAPACITÀ E COMPETENZE PERSONALI: Programmazione e coordinamento attività di ricerca clinica in oncologia. Coordinamento di gruppi di lavoro, collaborazione con esperti in altre discipline

PRIMA LINGUA Italiano

ALTRE LINGUE: Inglese

- Capacità di lettura: Ottima
- Capacità di scrittura: Ottima
- Capacità di espressione orale: Buona

CAPACITÀ E COMPETENZE RELAZIONALI

In grado di coordinare gruppi di lavoro composti da persone con competenze professionali sia affini che diverse.

CAPACITÀ E COMPETENZE ORGANIZZATIVE

In grado di coordinare gruppi di lavoro composti da persone con competenze professionali sia affini che diverse.

CAPACITÀ E COMPETENZE TECNICHE

Utilizzo supporti informatici con livello di competenza elevato

CAPACITÀ E COMPETENZE ARTISTICHE

Stesura di testi divulgativi, anche in forma di racconti.

ALTRE CAPACITÀ E COMPETENZE

PATENTE O PATENTI Patente B

ULTERIORI INFORMAZIONI

- Responsabile di **progetti di ricerca** sul carcinoma mammario (AIRC 2001-2006: finanziamento ottenuto euro 188.000,00; AIFA 2007: finanziamento ottenuto euro 631.000,00; Ministero salute 2008: finanziamento ottenuto 850.000,00; regione Liguria 2009: finanziamento ottenuto euro 137.000,00; Ministero salute finalizzata 2012: 348.900 euro; Ministero salute 2012 CCM: 40.000 come UO di progetto finanziato per 350.000 euro; AIRC 2013: finanziamento ottenuto: 208.000 euro; Ricerca su fondi 5 per mille IRCCS San Martino –IST 2014: finanziamento ottenuto: 150.000 euro; Ministero della salute, Conto capitale 2013: finanziamento ottenuto: 300.000 euro). Totale finanziamenti per progetti di ricerca: 2.850.000,00 euro
- Dal 2012: Membro del **Comitato Tecnico Scientifico** dell'Associazione Italiana per la Ricerca sul Cancro, Milano
- Dal 2014: Membro del **Comitato tecnico Scientifico** dell'IRCCS San Martino –IST, Genova
- Dal 2015: Membro del **Comitato Tecnico Scientifico** Della Fondazione Veronesi, Milano
- Dal 2015: componente gruppo di lavoro del **Consiglio Superiore di Sanità** – Ministero della Salute, Roma
- 2014-2015: membro del Comitato Direttivo **dell'Associazione Italiana di Oncologia Medica** (AIOM)
- Membro del Consiglio del consorzio Oncotech (Università degli Studi di Napoli)
- **Revisore** ed estensore di linee guida AIOM su: carcinoma mammario, preservazione della fertilità, fattori di crescita ematopoietici
- **Revisore** per le seguenti riviste internazionali: Annals of Oncology, Evidenced-based Oncology, Lung Cancer, The Lancet, Leukemia and Lymphoma, Expert review of Anti-cancer therapy, Oncology, Cancer Research, The Oncologist, European Journal of Cancer, Journal of Clinical Oncology

- **Revisore** per protocolli di studio per i seguenti enti: Cancer Research UK, Foundation against cancer, Bruxelles, EORTC
- **Autore e co-autore** di oltre 130 articoli scientifici pubblicati su riviste internazionali con impact factor. Totale IF: 592; IF medio: 8.59; H-index: 31

ALLEGATO: pubblicazioni su riviste scientifiche (PubMed)

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 196/03.

Genova, 25/10/2016

NOME E COGNOME (FIRMA) Lucia Del Mastro



Allegato: Pubblicazioni su riviste scientifiche (PubMed)

1. Lambertini M, Poggio F, Vaglica M, Blondeaux E, Del Mastro L.

News on the medical treatment of young women with early-stage HER2-negative breast cancer.
Expert Opin Pharmacother. 2016 Aug;17(12):1643-55

2. Schettini F, Buono G, Cardalesi C, Desideri I, De Placido S, Del Mastro L.

Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going.
Cancer Treat Rev. 2016 May;46:20-6

3. Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HA Jr, Peccatori FA, Costa M, Revelli A, Salvagno F, Gennari A, Ubaldi FM, La Sala GB, De Stefano C, Wallace WH, Partridge AH, Anserini P.

Cancer and fertility preservation: international recommendations from an expert meeting.
BMC Med. 2016 Jan 4;14:1.

4. Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, Giordano M, Garrone O, Levaggi A, Poggio F, Giraudo S, Bighin C, Vecchio C, Sertoli MR, Pronzato P, Del Mastro L; GIM Study Group

Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial.
JAMA. 2015 Dec 22-29;314(24):2632-40

5. Lambertini M, Anserini P, Del Mastro L.

Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors?
Eur J Cancer. 2016 Feb;54:163-4

6. Del Mastro L, Levaggi A, Michelotti A, Cavazzini G, Adami F, Scotto T, Piras M, Danese S, Garrone O, Durando A, Accortanzo V, Bighin C, Miglietta L, Pastorino S, Pronzato P, Castiglione F, Landucci E, Conte P, Bruzzi P.

5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial.
Breast Cancer Res Treat. 2016 Jan;155(1):117-26.

7. Montemurro F, Del Mastro L, De Laurentiis M, Puglisi F.

Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence.
Expert Rev Anticancer Ther. 2016;16(2):211-8

8. Del Mastro L, Rossi G, Lambertini M, Poggio F, Pronzato P.

New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients.
Cancer Treat Rev. 2016 Jan;42:18-23.

9. Lambertini M, Ferreira AR, Del Mastro L, Danesi R, Pronzato P.

Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.
Expert Opin Biol Ther. 2015;15(12):1799-817

10. Del Mastro L, Lambertini M.

Temporary Ovarian Suppression With Gonadotropin-Releasing Hormone Agonist During Chemotherapy for Fertility Preservation: Toward the End of the Debate?
Oncologist. 2015 Nov;20(11):1233-5.

11. Boero S, Morabito A, Banelli B, Cardinali B, Dozin B, Lunardi G, Piccioli P, Lastraioli S, Carosio R, Salvi S, Levaggi A, Poggio F, D'Alonzo A, Romani M, Del Mastro L, Poggi A, Pistillo MP.

Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.
J Transl Med. 2015 Oct 8;13:324. Erratum in: J Transl Med. 2016;14:24.

12. Lambertini M, Poggio F, Levaggi A, **Del Mastro L.**

Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis.

Obstet Gynecol. 2015 Oct;126(4):901.

13. Lambertini M, Ceppi M, Poggio F, Peccatori FA, Azim HA Jr, Ugolini D, Pronzato P, Loibl S, Moore HC, Partridge AH, Bruzzi P, **Del Mastro L.**

Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies.

Ann Oncol. 2015 Dec;26(12):2408-19.

14. Lambertini M, Bruzzi P, Poggio F, Pastorino S, Gardin G, Clavarezza M, Bighin C, Pronzato P, **Del Mastro L.**

Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial.

Support Care Cancer. 2016 Mar;24(3):1285-94.

15. **Del Mastro L**, Cazzaniga M, Solidoro P, Generali D, Bianchi G, Testore F, De Placido S.

Everolimus-based therapy in patients with hormone receptor-positive, HER2(-) advanced breast cancer: management considerations.

Future Oncol. 2015;11(16):2251-4.

16. Aurilio G, Gori S, Nolè F, Pruneri G, Coati F, Torri V, Lunardi G, Atzori F, La Verde N, Banna GL, Rossi A, **Del Mastro L**, Di Fabio F, Marcon I, Gebbia V, Loupakis F, Orlando L, Ciuffreda L, Amadio P, Luppi G, Redana S, Filippelli G, Gentile A, Collovà E.

Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology.

Tumori. 2016 Jan-Feb;102(1):108-13.

17. Lambertini M, Kamal NS, Peccatori FA, **Del Mastro L**, Azim HA Jr.

Exploring the safety of chemotherapy for treating breast cancer during pregnancy.

Expert Opin Drug Saf. 2015;14(9):1395-408.

18. Lambertini M, Ferreira AR, Poggio F, Puglisi F, Bernardo A, Montemurro F, Poletto E, Pozzi E, Rossi V, Risi E, Lai A, Zanardi E, Sini V, Ziliani S, Minuti G, Mura S, Grasso D, Fontana A, **Del Mastro L.**

Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.

Oncologist. 2015 Aug;20(8):880-9

19. Bogina G, Lunardi G, Coati F, Zamboni G, Gori S, Bortesi L, Marconi M, Cassandrini PA, Turazza M, Cortesi L, DeMatteis E, Ficarra G, Ibrahim T, Serra P, Medri L, Giraudi S, Lambertini M, Carli F, Foglietta J, Sidoni A, Nunzi M, Ficarella C, Diadema MR, **Del Mastro L.**

Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence.

Tumori. 2015 Jul-Aug;101(4):398-403.

20. Gori S, Foglietta J, Lunardi G, Inno A, Cardinali B, Millo E, **Del Mastro L**, Nunzi EG, Crinò L.

Pharmacokinetics of trastuzumab in haemodialysis.

Breast J. 2015 May-Jun;21(3):329-31.

- 21. Del Mastro L**, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F; Gruppo Italiano Mammella (GIM) investigators.
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Lancet. 2015 May 9;385(9980):1863-72.
- 22. Levaggi A**, De Maria A, Dozin B, Iacono G, Bighin C, Giraudi S, Lambertini M, D'Alonzo A, Poggio F, Pronzato P, **Del Mastro L**.
Incidence of hepatitis in patients with evidence of past or current hepatitis B or C during chemotherapy for early breast cancer.
Anticancer Res. 2014 Jul;34(7):3715-20.
- 23. Lambertini M**, Pinto AC, **Del Mastro L**.
Fertility issues in young breast cancer patients: what women want.
J Thorac Dis. 2014 Jun;6(6):584-8.
- 24. Cardinali B**, Lunardi G, Millo E, Armirotti A, Damonte G, Profumo A, Gori S, Iacono G, Levaggi A, **Del Mastro L**.
Trastuzumab quantification in serum: a new, rapid, robust ELISA assay based on a mimetic peptide that specifically recognizes trastuzumab.
Anal Bioanal Chem. 2014 Jul;406(18):4557-61
- 25. Puglisi F**, Fontanella C, Numico G, Sini V, Evangelista L, Monetti F, Gori S, **Del Mastro L**.
Follow-up of patients with early breast cancer: is it time to rewrite the story?
Crit Rev Oncol Hematol. 2014 Aug;91(2):130-41
- 26. Canavese G**, Bruzzi P, Catturich A, Vecchio C, Tomei D, **Del Mastro L**, Carli F, Guenzi M, Lacopo F, Dozin B.
A risk score model predictive of the presence of additional disease in the axilla in early-breast cancer patients with one or two metastatic sentinel lymph nodes.
Eur J Surg Oncol. 2014 Jul;40(7):835-42.
- 27. Gori S**, Lunardi G, Inno A, Foglietta J, Cardinali B, **Del Mastro L**, Crinò L.
Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases.
Ann Oncol. 2014 Apr;25(4):912-3.
- 28. Bertoldo F**, Silvestris F, Ibrahim T, Cognetti F, Generali D, Ripamonti CI, Amadori D, Colleoni MA, Conte P, **Del Mastro L**, De Placido S, Ortega C, Santini D
Targeting bone metastatic cancer: Role of the mTOR pathway.
Biochim Biophys Acta. 2014 Apr;1845(2):248-54
- 29. Sini V**, Lunardi G, Cirillo M, Turazza M, Bighin C, Giraudi S, Levaggi A, Piccioli P, Bisagni G, Gnani R, Stridi G, Porpiglia M, Picardo E, Ponzoni R, Marengo D, Mansutti M, Puglisi F, **Del Mastro L**.
Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole.
Br J Cancer. 2014 Mar 4;110(5):1133-8
- 30. Del Mastro L**, Ceppi M, Poggio F, Bighin C, Peccatori F, Demeestere I, Levaggi A, Giraudi S, Lambertini M, D'Alonzo A, Canavese G, Pronzato P, Bruzzi P.
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials.
Cancer Treat Rev. 2014 Jun;40(5):675-83.
- 31. Bozza C**, Puglisi F, Lambertini M, Osa EO, Manno M, **Del Mastro L**.
Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients.
Endocr Relat Cancer. 2014 Jan 21;21(1):R51-65

- 32. Lambertini M, Del Mastro L, Bellodi A, Pronzato P.**
The five "Ws" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs).
Crit Rev Oncol Hematol. 2014 Jan;89(1):112-28.
- 33. Gennari A, Del Mastro L.**
Anthracycline-free therapy for HER2-amplified breast cancer.
Lancet Oncol. 2013 Oct;14(11):1037-8.
- 34. Clavarezza M, Bordonaro R, Daniele B, Ferrandina G, Barni S, Turazza M, Coati F, De Matteis A, De Placido S, Cognetti F, Olmeo NA, Carrozza F, Bruzzi P, Del Mastro L; Gruppo Italiano Mammella.**
Dose-dense FEC followed by dose-dense ixabepilone as neoadjuvant treatment for breast cancer patients: a feasibility study.
Oncologist. 2013;18(8):924-5. Erratum in: *Oncologist.* 2013;18(10):1149.
- 35. Bighin C, Pronzato P, Del Mastro L.**
Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients.
Future Oncol. 2013 Jul;9(7):955-7.
- 36. Lambertini M, Anserini P, Levaggi A, Poggio F, Del Mastro L.**
Fertility counseling of young breast cancer patients.
J Thorac Dis. 2013 Jun;5 Suppl 1:S68-80.
- 37. Clavarezza M, Turazza M, Aitini E, Saracchini S, Garrone O, Durando A, De Placido S, Bisagni G, Levaggi A, Bighin C, Restuccia E, Scalamogna R, Galli A, Del Mastro L.**
Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
Breast. 2013 Aug;22(4):470-5.
- 38. Del Mastro L, Fabi A, Mansutti M, De Laurentiis M, Durando A, Merlo DF, Bruzzi P, La Torre I, Ceccarelli M, Kazeem G, Marchi P, Boy D, Venturini M, De Placido S, Cognetti F.**
Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.
BMC Cancer. 2013 Mar 28;13:164.
- 39. Arpino G, Generali D, Sapino A, Del Mastro L, Frassoldati A, de Laurentis M, Paolo P, Mustacchi G, Cazzaniga M, De Placido S, Conte P, Cappelletti M, Zanoni V, Antonelli A, Martinotti M, Puglisi F, Berruti A, Bottini A, Dogliotti L.**
Gene expression profiling in breast cancer: a clinical perspective.
Breast. 2013 Apr;22(2):109-20. Erratum in: *Breast.* 2016 Feb;25:86. Del Matro, Lucia [corrected to Del Mastro, Lucia].
- 40. Lunardi G, Piccioli P, Bruzzi P, Notaro R, Lastraioli S, Serra M, Marroni P, Bighin C, Mansutti M, Puglisi F, Porpiglia M, Ponzzone R, Bisagni G, Garrone O, Cavazzini G, Clavarezza M, Del Mastro L.**
Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole.
Breast Cancer Res Treat. 2013 Jan;137(1):167-74.
- 41. Del Mastro L, Lambertini M, Bighin C, Levaggi A, D'Alonzo A, Giraudi S, Pronzato P.**
Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.
Expert Rev Anticancer Ther. 2012 Nov;12(11):1391-405.
- 42. Clavarezza M, Mustacchi G, Casadei Gardini A, Del Mastro L, De Matteis A, Riccardi F, Adamo V, Aitini E, Amoroso D, Marchetti P, Gori S, Carrozza F, Maiello E, Giotto F, Dondi D, Venturini M.**
Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study.
BMC Cancer. 2012 Jun 6;12:216.

43. Lambertini M, **Del Mastro L**, Gardin G, Levaggi A, Bighin C, Giraudi S, Pronzato P.
Stevens-Johnson syndrome after treatment with bendamustine.
Leuk Res. 2012 Jul;36(7):e153-4.
44. Bedognetti D, Sertoli MR, Pronzato P, **Del Mastro L**, Venturini M, Taveggia P, Zanardi E, Siffredi G, Pastorino S, Queirolo P, Gardin G, Wang E, Monzeglio C, Boccardo F, Bruzzi P.
Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial.
J Natl Cancer Inst. 2011 Oct 19;103(20):1529-39.
45. Danova M, Barni S, **Del Mastro L**, Danesi R, Pappagallo GL.
Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors.
Expert Rev Anticancer Ther. 2011 Aug;11(8):1303-13.
46. **Del Mastro L**, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, Giordano M, Garrone O, Pronzato P, Bighin C, Levaggi A, Giraudi S, Cresti N, Magnolfi E, Scotto T, Vecchio C, Venturini M.
Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
JAMA. 2011 Jul 20;306(3):269-76.
47. **Del Mastro L**.
Temporary ovarian suppression with goserelin and ovarian function protection in patients with breast cancer undergoing chemotherapy.
J Clin Oncol. 2011 Aug 20;29(24):3339-40; author reply 3341-2.
48. Canavese G, Dozin B, Vecchio C, Tomei D, Villa G, Carli F, **Del Mastro L**, Levaggi A, Rossello C, Spinaci S, Bruzzi P, Catturich A.
Accuracy of sentinel lymph node biopsy after neo-adjuvant chemotherapy in patients with locally advanced breast cancer and clinically positive axillary nodes.
Eur J Surg Oncol. 2011 Aug;37(8):688-94.
49. Lambertini M, Pronzato P, Giraudi S, Levaggi A, Bighin C, **Del Mastro L**.
Letrozole withdrawal response in locally advanced breast cancer.
Ann Oncol. 2011 Aug;22(8):1927-8
50. **Del Mastro L**, Giraudi S, Levaggi A, Pronzato P.
Medical approaches to preservation of fertility in female cancer patients.
Expert Opin Pharmacother. 2011 Feb;12(3):387-96.
51. Bighin C, Lunardi G, **Del Mastro L**, Marroni P, Taveggia P, Levaggi A, Giraudi S, Pronzato P.
Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated with aromatase inhibitors.
Oncologist. 2010;15(12):1270-2.
52. Azim HA Jr, **Del Mastro L**, Scarfone G, Peccatori FA.
Treatment of breast cancer during pregnancy: regimen selection, pregnancy monitoring and more...
Breast. 2011 Feb;20(1):1-6
53. **Del Mastro L**, Levaggi A, Giraudi S, Pronzato P.
Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives.
Cancer Treat Rev. 2011 May;37(3):208-11.
54. **Del Mastro L**, Bighin C, Bini G, Giraudi S, Taveggia P, Levaggi A, Canavese G, Rescinito G, Pronzato P.
Trastuzumab before breast surgery: is concurrent administration with anthracycline-containing chemotherapy necessary?
Ann Oncol. 2010 Jun;21(6):1376-7.

55. Gascon P, Pirker R, **Del Mastro L**, Durrwell L.
Effects of CERA (continuous erythropoietin receptor activator) in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy: results of a phase II study.
Ann Oncol. 2010 Oct;21(10):2029-39.
56. Venturini M, Bighin C, Puglisi F, Olmeo N, Aitini E, Colucci G, Garrone O, Paccagnella A, Marini G, Crinò L, Mansutti M, Baconnet B, Barbato A, **Del Mastro L**.
A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer.
Breast. 2010 Oct;19(5):333-8.
57. Bighin C, **Del Mastro L**, Canavese G, Carli F, Taveggia P, Levaggi A, Giraudi S, Pronzato P.
Use in current clinical practice of 70-gene signature in early breast cancer.
Int J Cancer. 2010 Dec 1;127(11):2736-7.
58. Banelli B, Casciano I, Di Vinci A, Gatteschi B, Levaggi A, Carli F, Bighin C, Salvi S, Allemanni G, Ghiorzo P, Pronzato P, Venturini M, Romani M, **Del Mastro L**.
Pathological and molecular characteristics distinguishing contralateral metastatic from new primary breast cancer.
Ann Oncol. 2010 Jun;21(6):1237-42.
59. Morabito A, Dozin B, Salvi S, Pasciucco G, Balbi G, Laurent S, Pastorino S, Carli F, Truini M, Bruzzi P, **Del Mastro L**, Pistillo MP.
Analysis and clinical relevance of human leukocyte antigen class I, heavy chain, and beta2-microglobulin downregulation in breast cancer.
Hum Immunol. 2009 Jul;70(7):492-5
60. Montemurro F, Aglietta M, **Del Mastro L**.
Aromatase inhibitors as adjuvant therapy for breast cancer.
J Clin Oncol. 2009 May 20;27(15):2566-7.
61. **Del Mastro L**.
The difficult decision-making process for using or not using adjuvant chemotherapy in premenopausal endocrine-responsive breast cancer patients.
Ann Oncol. 2008 Jul;19(7):1213-5.
62. Crivellari D, Sun Z, Coates AS, Price KN, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens RJ, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, **Del Mastro L**, Gladieff L, Rabaglio M, Smith IE, Chirgwin JH, Goldhirsch A.
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.
J Clin Oncol. 2008 Apr 20;26(12):1972-9.
63. Piccioli P, Serra M, Pedemonte S, Balbi G, Loiacono F, Lastraioli S, Gargiulo L, Morabito A, Zuccaro D, **Del Mastro L**, Pistillo MP, Venturini M, De Angioletti M, Notaro R.
Hexaprimer amplification refractory mutation system PCR for simultaneous single-tube genotyping of 2 close polymorphisms.
Clin Chem. 2008 Jan;54(1):227-9.
64. **Del Mastro L**, Dozin B, Aitini E, Catzeddu T, Baldini E, Contu A, Durando A, Danese S, Cavazzini G, Canavese G, Bruzzi P, Pronzato P, Venturini M; GONO-MIG Group
Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group.
Ann Oncol. 2008 Feb;19(2):299-307.
65. **Del Mastro L**, Clavarezza M, Venturini M.

Reducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitors.
Cancer Treat Rev. 2007 Dec;33(8):681-7.

66. Clavarezza M, **Del Mastro L**, Pronzato P, Bruzzi P, Venturini M.

Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.

J Natl Cancer Inst. 2007 Jul 4;99(13):1050-1; author reply 1051-2.

67. Gridelli C, Aapro MS, Barni S, Beretta GD, Colucci G, Daniele B, **Del Mastro L**, Di Maio M, De Petris L, Perrone F, Thatcher N, De Marinis F.

Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel.

Crit Rev Oncol Hematol. 2007 Jul;63(1):53-64.

68. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, **Del Mastro L**, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM; Intergroup Exemestane Study.

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.

Lancet. 2007 Feb 17;369(9561):559-70. Erratum in: Lancet. 2007 Mar 17;369(9565):906.

69. Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, **Del Mastro L**, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A.

Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.

J Clin Oncol. 2007 Feb 10;25(5):486-92.

70. Venturini M, **Del Mastro L**.

Safety of adjuvant aromatase inhibitor therapy.

Cancer Treat Rev. 2006 Nov;32(7):548-56.

71. **Del Mastro L**, Venturini M.

Fertility preservation strategies for breast cancer patients.

J Clin Oncol. 2006 Sep 1;24(25):4220-1; author reply 4221-2.

72. **Del Mastro L**, Catzeddu T, Venturini M.

Infertility and pregnancy after breast cancer: current knowledge and future perspectives.

Cancer Treat Rev. 2006 Oct;32(6):417-22.

73. Clavarezza M, **Del Mastro L**, Venturini M.

Taxane-containing chemotherapy in the treatment of early breast cancer patients.

Ann Oncol. 2006 Jun;17 Suppl 7:vii22-6.

74. Bertelli G, Garrone O, Merlano M, Occelli M, Bertolotti L, Castiglione F, Pepi F, Fusco O, **Del Mastro L**, Leonard RC.

Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.

Oncology. 2005;69(6):471-7

75. Venturini M, **Del Mastro L**, Aitini E, Baldini E, Caroti C, Contu A, Testore F, Brema F, Pronzato P, Cavazzini G, Sertoli MR, Canavese G, Rosso R, Bruzzi P.

Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.

J Natl Cancer Inst. 2005 Dec 7;97(23):1724-33.

76. Venturini M, Bighin C, Monfardini S, Cappuzzo F, Olmeo N, Durando A, Puglisi F, Nicoletto O, Lambiase A, **Del Mastro L**.

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer.
Breast Cancer Res Treat. 2006 Jan;95(1):45-53.

77. Del Mastro L, Catzeddu T, Boni L, Bell C, Sertoli MR, Bighin C, Clavarezza M, Testa D, Venturini M.
Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients.
Ann Oncol. 2006 Jan;17(1):74-8

78. Bertelli G, Garrone O, Bertolotti L, Occelli M, Conforti S, Marzano N, Febbraro A, Carlini P, Liossi C, **Del Mastro L**, Leonard RC.
Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer.
Oncology. 2005;68(4-6):364-70.

79. Del Mastro L, Bruzzi P, Nicolò G, Cavazzini G, Contu A, D'Amico M, Lavarello A, Testore F, Castagneto B, Aitini E, Perdelli L, Bighin C, Rosso R, Venturini M.
HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients.
Br J Cancer. 2005 Jul 11;93(1):7-14.

80. Bruzzi P, Del Mastro L, Sormani MP, Bastholt L, Danova M, Focan C, Fountzilas G, Paul J, Rosso R, Venturini M.
Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients.
J Clin Oncol. 2005 Aug 1;23(22):5117-25

81. Del Mastro L, Venturini M.
ATAC trial update.
Lancet. 2005 Apr 2-8;365(9466):1225; author reply 1225-6.

82. Del Mastro L, Perrone F, Repetto L, Manzione L, Zagonel V, Fratino L, Marengo D, Venturini M, Maggi E, Bighin C, Catzeddu T, Venturino A, Rosso R; Gruppo Italiano di Oncologia Geriatrica (GIOGer).
Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer).
Ann Oncol. 2005 Feb;16(2):253-8.

83. Del Mastro L
[The AIOM (Italian Association of Medical Oncology) practice guidelines for breast neoplasms].
Tumori. 2004 Mar-Apr;90(2):1-8. Italian.

84. Catzeddu T, Bertelli G, **Del Mastro L**, Venturini M.
Sentinel lymph node biopsy in breast cancer patients: the medical oncology perspective.
J Surg Oncol. 2004 Mar;85(3):129-32. Review

85. Repetto L, Comandini D, Mammoliti S, Pietropaolo M, **Del Mastro L**.
Weekly paclitaxel in elderly patients with advanced breast cancer: a dose-finding study.
Drugs R D. 2004;5(1):11-5.

86. Del Mastro L
[Epoetin in cancer patients. Guidelines of the ASCO and the ASH for evidence-based clinical practice].
Tumori. 2003 Jul-Aug;89(4):1-12. Italian.

87. Lunardi G, Vannozzi MO, Bighin C, **Del Mastro L**, Stevani I, Schettini G, Venturini M.
Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients.
Ann Oncol. 2003 Aug;14(8):1222-6.

- 88. Venturini M, Durando A, Garrone O, Colozza MA, Contu A, Stevani I, Genta F, Bighin C, Lambiase A, Del Mastro L.**
Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma.
Cancer. 2003 Mar 1;97(5):1174-80.
- 89. Bertelli G, Venturini M, Del Mastro L, Bergaglio M, Sismondi P, Biglia N, Venturini S, Porcile G, Pronzato P, Costantini M, Rosso R.**
Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study.
Ann Oncol. 2002 Jun;13(6):883-8.
- 90. Venturini M, Del Mastro L, Garrone O, Angiolini C, Merlano M, Bergaglio M, Tolino G, Lambiase A, Baldini A, Canavese G, Rosso R.**
Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer.
Ann Oncol. 2002 Apr;13(4):546-52.
- 91. Del Mastro L, Maggi E, Catzeddu T, Hazini A, Bell C.**
Is it possible to use anthracyclines in patients older than 70 years? Contra.
Tumori. 2002 Jan-Feb;88(1 Suppl 1):S136-7.
- 92. Lunardi G, Venturini M, Vannozzi MO, Tolino G, Del ML, Bighin C, Schettini G, Esposito M.**
Influence of alternate sequences of epirubicin and docetaxel on the pharmacokinetic behaviour of both drugs in advanced breast cancer.
Ann Oncol. 2002 Feb;13(2):280-5.
- 93. Del Mastro L, Costantini M, Morasso G, Bonci F, Bergaglio M, Banducci S, Viterbori P, Conte P, Rosso R, Venturini M.**
Impact of two different dose-intensity chemotherapy regimens on psychological distress in early breast cancer patients.
Eur J Cancer. 2002 Feb;38(3):359-66.
- 94. Venturini M, Michelotti A, Papaldo P, Del Mastro L, Bergaglio M, Lionetto R, Lunardi G, Sguotti C, Frevola L, Donati S, Rosso R, Cognetti F.**
Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients.
Ann Oncol. 2001 Aug;12(8):1097-106. Erratum in: Ann Oncol 2001 Oct;12(10):1498.
- 95. Del Mastro L, Venturini M, Viscoli C, Bergaglio M, Signorini A, Bighin C, Bertelli G, Semino C, Pietra G, Bertoglio S, Sertoli MR, Lambiase A, Rosso R, Melioli G.**
Intensified chemotherapy supported by DMSO-free peripheral blood progenitor cells in breast cancer patients.
Ann Oncol. 2001 Apr;12(4):505-8.
- 96. Sanguineti G, Del Mastro L, Guenzi M, Ricci P, Cavallari M, Canavese G, Stevani I, Venturini M.**
Impact of chemotherapy dose-density on radiotherapy dose-intensity after breast conserving surgery.
Ann Oncol. 2001 Mar;12(3):373-8
- 97. Del Mastro L, Venturini M, Lionetto R, Carnino F, Guarneri D, Gallo L, Contu A, Pronzato P, Vesentini L, Bergaglio M, Comis S, Rosso R.**
Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group.
J Clin Oncol. 2001 Apr 15;19(8):2213-21.

98. Bertelli G, Queirolo P, Vecchio S, Angiolini C, Bergaglio M, **Del Mastro L**, Signorini A, Valenzano M, Venturini M.
Toremifene as a substitute for adjuvant tamoxifen in breast cancer patients.
Anticancer Res. 2000 Sep-Oct;20(5C):3659-61.
99. Morasso G, Costantini M, Viterbori P, Bonci F, **Del Mastro L**, Musso M, Garrone O, Venturini M.
Predicting mood disorders in breast cancer patients.
Eur J Cancer. 2001 Jan;37(2):216-23.
100. Pronzato P, Queirolo P, Vecchio S, Lionetto R, **Del Mastro L**, Venturini M, Gardin G, Alama A, Sertoli MR.
Thymidine labeling index analysis in early breast cancer patients randomized to receive perioperative chemotherapy.
Oncology. 2001;60(1):88-93.
101. Michelotti A, Venturini M, Tibaldi C, Bengala C, Gallo L, Carnino F, **Del Mastro L**, Lionetto R, Montanaro E, Rosso R, Conte P.
Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients.
Breast Cancer Res Treat. 2000 Jan;59(2):133-9.
102. Venturini M, Lunardi G, **Del Mastro L**, Vannozzi MO, Tolino G, Numico G, Viale M, Pastrone I, Angiolini C, Bertelli G, Straneo M, Rosso R, Esposito M.
Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity.
J Clin Oncol. 2000 May;18(10):2116-25.
103. **Del Mastro L**, Gennari A, Donati S.
Chemotherapy of non-small-cell lung cancer: role of erythropoietin in the management of anemia.
Ann Oncol. 1999;10 Suppl 5:S91-4. Review.
104. Esposito M, Venturini M, Vannozzi MO, Tolino G, Lunardi G, Garrone O, Angiolini C, Viale M, Bergaglio M, **Del Mastro L**, Rosso R.
Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients.
J Clin Oncol. 1999 Apr;17(4):1132
105. **Del Mastro L**, Venturini M.
Strategies for the Use of Epoetin Alfa in Breast Cancer Patients.
103. Costantini M, Musso M, Viterbori P, Bonci F, **Del Mastro L**, Garrone O, Venturini M, Morasso G.
Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale.
Support Care Cancer. 1999 May;7(3):121-7.
106. **Del Mastro L**, Venturini M.
Treatment of breast cancer.
N Engl J Med. 1999 Jan 28;340(4):319-20. No abstract available.
107. Conte PF, **Del Mastro L**.
Putting the taxanes to work: unanswered questions.
Recent Results Cancer Res. 1998;152:305-13. Review.
108. Fontanini G, **Del Mastro L**, Bevilacqua G.
Determination of angiogenesis in human neoplasms: current prognostic and therapeutic implications.
Forum (Genova). 1998 Apr-Jun;8(2):128-42. Review.
109. Venturini M, **Del Mastro L**.
More on dose-intensity of anthracyclines in breast cancer.
Ann Oncol. 1998 Apr;9(4):461. No abstract available.

- 110.** Dini D, **Del Mastro L**, Gozza A, Lionetto R, Garrone O, Forno G, Vidili G, Bertelli G, Venturini M. The role of pneumatic compression in the treatment of postmastectomy lymphedema. A randomized phase III study. *Ann Oncol.* 1998 Feb;9(2):187-90.
- 111.** Bertelli G, Venturini M, **Del Mastro L**, Garrone O, Cosso M, Gustavino C, Cusimano E, Guido T, Nicolò G, Rosso R. Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. *Breast Cancer Res Treat.* 1998 Jan;47(1):41-6.
- 112.** Rosso R, **Del Mastro L**, Venturini M, Bergaglio M, Pasquetti W, Garrone O. [Use of erythropoietin in oncology]. *Tumori.* 1997 Jul-Aug;83(4 Suppl 2):S26-30. Review. Italian.
- 113.** **Del Mastro L**, Venturini M, Lionetto R, Garrone O, Melioli G, Pasquetti W, Sertoli MR, Bertelli G, Canavese G, Costantini M, Rosso R. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. *J Clin Oncol.* 1997 Jul;15(7):2715-21.
- 114.** **Del Mastro L**, Venturini M, Sertoli MR, Rosso R. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. *Breast Cancer Res Treat.* 1997 Apr;43(2):183-90. Review.
- 115.** **Del Mastro L**, Venturini M, Costantini M, Garrone O, Sertoli MR, Bertelli G, Machi AM, Rosso R. Paradoxical effect of cytotoxic chemotherapy on anemia in cancer patients with beta-thalassemia minor. *J Natl Cancer Inst.* 1997 Mar 19;89(6):455-6.
- 116.** Venturini M, Michelotti A, **Del Mastro L**, Gallo L, Carnino F, Garrone O, Tibaldi C, Molea N, Bellina RC, Pronzato P, Cyrus P, Vinke J, Testore F, Guelfi M, Lionetto R, Bruzzi P, Conte PF, Rosso R. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. *J Clin Oncol.* 1996 Dec;14(12):3112-20.
- 117.** Venturini M, Bruzzi P, **Del Mastro L**, Garrone O, Bertelli G, Guelfi M, Pastorino S, Rosso R, Sertoli MR. Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer. *J Clin Oncol.* 1996 Mar;14(3):764-73.
- 118.** Venturini M, **Del Mastro L**, Testore F, Danova M, Garrone O, Lanfranco C, Latini F, Sertoli MR, Lionetto R, Queirolo P, Ardizzoni A, Rosso R. Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer. *Cancer Chemother Pharmacol.* 1996;38(6):487-94.
- 119.** Bertelli G, Gozza A, Forno GB, Vidili MG, Silvestro S, Venturini M, **Del Mastro L**, Garrone O, Rosso R, Dini D. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. *J Clin Oncol.* 1995 Nov;13(11):2851-5.
- 120.** Sertoli MR, Bruzzi P, Pronzato P, Queirolo P, Amoroso D, **Del Mastro L**, Venturini M, Vigani A, Bertelli G, Campora E, et al.

Randomized cooperative study of perioperative chemotherapy in breast cancer.
J Clin Oncol. 1995 Nov;13(11):2712-21.

121. Del Mastro L, Venturini M, Giannessi PG, Vigani A, Garrone O, Carnino F, Russo P, Galletti P, Rosso R, Conte PF.

Intraperitoneal infusion of recombinant human tumor necrosis factor and mitoxantrone in neoplastic ascites: a feasibility study.

Anticancer Res. 1995 Sep-Oct;15(5B):2207-12.

122. Del Mastro L, Costantini M, Bianco AR.

Adjuvant chemotherapy in breast cancer.

N Engl J Med. 1995 Aug 31;333(9):596; author reply 597. No abstract available.

123. Venturini M, **Del Mastro L**, Melioli G, Balleari E, Garrone O, Pasquetti W, Bason C, Ghio R, Bruzzi P, Rosso R.

Release of peripheral blood progenitor cells during standard dose cyclophosphamide, epidoxorubicin, 5-fluorouracil regimen plus granulocyte colony stimulating factor for breast cancer therapy.

124. Perrone F, De Placido S, Carlomagno C, Gravina A, De Laurentiis M, **Del Mastro L**, Gridelli C, Pagliarulo C, Bianco AR.

Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study.

Am J Clin Oncol. 1994 Jun;17(3):218-22.

125. Del Mastro L, Garrone O, Guenzi M, Cafiero F, Nicolò G, Rosso R, Venturini M.

Angiosarcoma of the residual breast after conservative surgery and radiotherapy for primary carcinoma.

Ann Oncol. 1994 Feb;5(2):163-5. Review.

126. Del Mastro L, Garrone O, Sertoli MR, Canavese G, Catturich A, Guenzi M, Rosso R, Venturini M.

A pilot study of accelerated cyclophosphamide, epirubicin and 5-fluorouracil plus granulocyte colony stimulating factor as adjuvant therapy in early breast cancer.

Eur J Cancer. 1994;30A(5):606-10.

127. Venturini M, **Del Mastro L**, Ardizzoni A, Sertoli MR, Mariani GL, Pennucci MC, Garrone O, Silvestro S, Addamo GF, Queirolo P, et al.

High dose intensity chemotherapy without bone marrow support: role of granulocyte-macrophage colony-stimulating factor.

Ann N Y Acad Sci. 1993 Nov 30;698:389-97. Review. No abstract available

128. Bianco AR, De Placido S, Perrone F, Carlomagno C, De Laurentiis M, **Del Mastro L**, Lauria R, Marinelli A, Gallo C.

Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer.

Ann N Y Acad Sci. 1993 Nov 30;698:330-8. No abstract available.

129. Garrone O, **Del Mastro L**, Mariani GL, Ardizzoni A, Venturini M, Rosso R.

[Feasibility of a cyclophosphamide methotrexate and 5-fluorouracil regime intravenously administered with and without granulocyte-colony stimulating factor in surgically treated breast carcinoma].

Minerva Med. 1993 Sep;84(9):467-72. Italian.

130. Bianco AR, **Del Mastro L**, Gallo C, Perrone F, Matano E, Pagliarulo C, De Placido S.

Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer.

Br J Cancer. 1991 May;63(5):799-803.

131. De Placido S, Gallo C, Marinelli A, Perrone F, Pagliarulo C, Petrella G, Delrio G, D'Istria M, **Del Mastro L**, Bianco AR.

Steroid hormone receptor levels and adjuvant tamoxifen in early breast cancer. Ten year results of the Naples (GUN) Study.
Breast Cancer Res Treat. 1990 Sep;16(2):111-7